MCID: ESP024
MIFTS: 62

Esophagitis

Categories: Gastrointestinal diseases, Infectious diseases

Aliases & Classifications for Esophagitis

MalaCards integrated aliases for Esophagitis:

Name: Esophagitis 12 30 56 45 15 74
Acute Esophagitis 12 74

Classifications:



External Ids:

Disease Ontology 12 DOID:11963
ICD9CM 36 530.1 530.10
MeSH 45 D004941
NCIt 51 C9224
SNOMED-CT 69 16761005
ICD10 34 K20 K20.9

Summaries for Esophagitis

MalaCards based summary : Esophagitis, also known as acute esophagitis, is related to peptic esophagitis and esophageal disease, and has symptoms including pain in esophagus (finding) An important gene associated with Esophagitis is CCL26 (C-C Motif Chemokine Ligand 26), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Trimebutine and Rabeprazole have been mentioned in the context of this disorder. Affiliated tissues include testes, smooth muscle and bone, and related phenotypes are hematopoietic system and growth/size/body region

Wikipedia : 77 Esophagitis (British spelling oesophagitis) (Greek οἰσοφάγος "gullet" and -itis "inflammation") is a... more...

Related Diseases for Esophagitis

Diseases in the Esophagitis family:

Bacterial Esophagitis Viral Esophagitis

Diseases related to Esophagitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1123)
# Related Disease Score Top Affiliating Genes
1 peptic esophagitis 33.7 CXCL8 CYP2C19 HRH2 IL1B
2 esophageal disease 33.4 CCL26 HRH2 PTGS2 TP53
3 esophagitis, eosinophilic, 1 33.4 CCL11 CCL26 IL13 IL5 TSLP
4 gastroesophageal reflux 32.3 CCL26 CXCL8 CYP2C19 HRH2 IL1B PTGS2
5 kaposi sarcoma 31.6 CCR3 CXCL8 IL6 TP53
6 helicobacter pylori infection 30.9 CXCL8 CYP2C19 IL1B
7 acquired immunodeficiency syndrome 30.8 IL1B IL6 TP53
8 gastric adenocarcinoma 30.5 CXCL8 IL1B PTGS2 TP53
9 chagas disease 30.5 CXCL8 IL1B IL6 TGFB1
10 gastritis 30.5 CXCL8 HRH2 IL1B PTGS2
11 acute respiratory distress syndrome 30.4 CXCL8 IL1B IL6
12 atrophic gastritis 30.4 CXCL8 IL1B TP53
13 hypereosinophilic syndrome 30.4 CCL11 IL13 IL5
14 duodenal ulcer 30.3 CXCL8 CYP2C19 HRH2 IL1B
15 pharyngitis 30.3 CXCL8 IL1B PTGS2
16 colitis 30.2 CXCL8 IL1B IL6 PTGS2
17 sleep apnea 30.2 CXCL8 IL1B IL6
18 dyspepsia 30.1 CXCL8 CYP2C19 HRH2 PTGS2
19 meningitis 30.1 CXCL8 IL1B IL6
20 interstitial lung disease 30.1 CXCL8 IL1B IL6 TGFB1
21 cytomegalovirus infection 30.1 CXCL8 IL1B IL6
22 peptic ulcer disease 30.1 CXCL8 CYP2C19 HRH2 IL1B PTGS2
23 eosinophilic gastroenteritis 30.1 CCL11 IL5 TSLP
24 cytokine deficiency 30.1 IL13 IL5
25 spinal cord injury 30.0 CXCL8 IL6 TGFB1
26 gastric ulcer 30.0 CXCL8 CYP2C19 HRH2 IL1B PTGS2
27 osteomyelitis 30.0 CXCL8 IL1B IL6
28 peritonitis 30.0 CXCL8 IL1B IL6
29 laryngitis 29.9 HRH2 IL1B IL6 TGFB1
30 periodontitis 29.8 CXCL8 IL1B IL6
31 allergic contact dermatitis 29.7 CXCL8 IL1B IL5
32 recurrent respiratory papillomatosis 29.7 PTGS2 TP53
33 pneumonia 29.7 CCL11 CXCL8 IL13 IL1B IL5 IL6
34 cholangiocarcinoma 29.7 IL6 PTGS2 TGFB1 TP53
35 ureteral obstruction 29.6 PTGS2 TGFB1 TP53
36 bacterial infectious disease 29.6 CXCL8 IL1B IL6
37 squamous cell carcinoma, head and neck 29.6 CXCL8 PTGS2 TGFB1 TP53
38 large intestine cancer 29.6 CXCL8 IL1B IL6 PTGS2 TP53
39 arthritis 29.6 CXCL8 IL1B IL6 PTGS2 TGFB1
40 newborn respiratory distress syndrome 29.6 CXCL8 IL1B IL6
41 lung disease 29.6 CXCL8 IL13 IL1B IL5 IL6 TGFB1
42 active peptic ulcer disease 29.6 HRH2 PTGS2
43 bacterial meningitis 29.6 CXCL8 IL1B IL6
44 cystitis 29.6 CXCL8 IL6 PTGS2
45 contact dermatitis 29.6 CXCL8 IL1B IL5 IL6
46 aging 29.6 SOD2 TGFB1 TP53
47 bullous pemphigoid 29.5 CCL11 DSG1 IL5
48 otitis media 29.5 CCL11 CXCL8 IL1B IL6
49 myocardial infarction 29.5 CYP2C19 IL1B IL6 POSTN PTGS2
50 synovitis 29.5 CXCL8 IL1B IL6

Comorbidity relations with Esophagitis via Phenotypic Disease Network (PDN): (show top 50) (show all 112)


Active Peptic Ulcer Disease Acute Cystitis
Acute Maxillary Sinusitis Acute Pancreatitis
Alcoholic Gastritis Allergic Rhinitis
Angina Pectoris Anxiety
Aortic Valve Disease 1 Atrophic Gastritis
Basilar Artery Insufficiency Benign Essential Hypertension
Bronchiectasis Bronchitis
Bronchopneumonia Cerebrovascular Disease
Cholecystitis Cholestasis
Chronic Intestinal Vascular Insufficiency Chronic Kidney Failure
Chronic Maxillary Sinusitis Chronic Myocardial Ischemia
Chronic Pulmonary Heart Disease Chronic Rhinitis
Chylomicron Retention Disease Conn's Syndrome
Conversion Disorder Cystitis
Deficiency Anemia Dependent Personality Disorder
Dermatomycosis Diabetic Polyneuropathy
Duodenitis Dyskinesia of Esophagus
Dysthymic Disorder Esophageal Cancer
Esophageal Candidiasis Esophageal Disease
Esophageal Varix First-Degree Atrioventricular Block
Gallbladder Disease Gastrin Secretion Abnormality
Gastritis, Familial Giant Hypertrophic Gastroesophageal Reflux
Generalized Anxiety Disorder Generalized Atherosclerosis
Heart Disease Hepatitis
Hyperlipoproteinemia, Type Iv Hyperlipoproteinemia, Type V

Graphical network of the top 20 diseases related to Esophagitis:



Diseases related to Esophagitis

Symptoms & Phenotypes for Esophagitis

UMLS symptoms related to Esophagitis:


pain in esophagus (finding)

MGI Mouse Phenotypes related to Esophagitis:

47 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.23 CCL11 CCR3 IL13 IL1B IL5 IL6
2 growth/size/body region MP:0005378 10.22 DSG1 IL13 IL1B IL5 IL6 POSTN
3 homeostasis/metabolism MP:0005376 10.21 CCR3 HRH2 IL13 IL1B IL5 IL6
4 immune system MP:0005387 10.18 CCL11 CCR3 IL13 IL1B IL5 IL6
5 digestive/alimentary MP:0005381 10.1 HRH2 IL13 IL5 IL6 PTGS2 TGFB1
6 adipose tissue MP:0005375 10.05 DSG1 IL6 POSTN PTGS2 SOD2 TGFB1
7 integument MP:0010771 10.02 DSG1 IL13 IL1B IL6 PTGS2 SOD2
8 muscle MP:0005369 9.87 IL13 IL6 POSTN PTGS2 SOD2 TGFB1
9 neoplasm MP:0002006 9.86 IL1B IL5 IL6 POSTN PTGS2 SOD2
10 reproductive system MP:0005389 9.76 IL13 IL5 IL6 POSTN PTGS2 SOD2
11 respiratory system MP:0005388 9.61 CCL11 CCR3 IL13 IL5 IL6 PTGS2
12 skeleton MP:0005390 9.23 DSG1 IL13 IL1B IL6 POSTN PTGS2

Drugs & Therapeutics for Esophagitis

Drugs for Esophagitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 402)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trimebutine Approved Phase 4 39133-31-8
2
Rabeprazole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 117976-89-3 5029
3
Dexlansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 138530-94-6, 103577-45-3 9578005
4
Lansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 103577-45-3 3883
5
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 73590-58-6 4594
6
Domperidone Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 57808-66-9 3151
7
Dopamine Approved Phase 4,Phase 3,Not Applicable 62-31-7, 51-61-6 681
8
Calcium polycarbophil Approved Phase 4 126040-58-2
9
Esomeprazole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
10
Fluticasone Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 90566-53-3 62924
11
leucovorin Approved Phase 4,Phase 3,Phase 1,Phase 2 58-05-9 6006 143
12
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 150399-23-8, 137281-23-3 60843 446556
13
Zinc Approved, Investigational Phase 4,Not Applicable 7440-66-6 32051
14
Pantoprazole Approved Phase 4,Phase 3,Phase 2,Phase 1 102625-70-7 4679
15
Budesonide Approved Phase 4,Phase 3,Phase 2,Not Applicable 51333-22-3 63006 5281004
16
Citalopram Approved Phase 4 59729-33-8 2771
17
Magnesium hydroxide Approved, Investigational Phase 4,Phase 2,Phase 3 1309-42-8
18
Ethanol Approved Phase 4 64-17-5 702
19
Metoclopramide Approved, Investigational Phase 4,Phase 3 364-62-5 4168
20
Ranitidine Approved Phase 4,Phase 3,Phase 2,Phase 1 66357-59-3, 66357-35-5 3001055
21
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
22
Deferasirox Approved, Investigational Phase 4 201530-41-8 5493381
23
Verapamil Approved Phase 4 52-53-9 2520
24
Prucalopride Approved Phase 4 179474-81-8
25
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
26
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
27
Ziprasidone Approved Phase 4 146939-27-7 60854
28
Clozapine Approved Phase 4 5786-21-0 2818
29
Lithium carbonate Approved Phase 4 554-13-2
30
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
31
Asenapine Approved Phase 4 65576-45-6, 85650-56-2 3001386
32
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
33
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
34
Clarithromycin Approved Phase 4 81103-11-9 84029
35
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 59-30-3 6037
36
Serine Approved, Nutraceutical Phase 4 56-45-1 5951
37
SB-649868 Experimental, Investigational Phase 4,Not Applicable 110-16-7, 110-17-8 444972
38 Mosapride Investigational Phase 4,Not Applicable 112885-41-3
39 Rebamipide Investigational Phase 4 90098-04-7
40
Polaprezinc Experimental Phase 4 107667-60-7
41
Dabigatran Investigational Phase 4 211914-51-1
42 Parasympatholytics Phase 4
43 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Anti-Ulcer Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
45 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Antacids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
47 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
48 Proton Pump Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
49 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Dopamine Agents Phase 4,Phase 3,Not Applicable

Interventional clinical trials:

(show top 50) (show all 811)
# Name Status NCT ID Phase Drugs
1 Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole Unknown status NCT02986685 Phase 4 Trimebutine Maleate;rabeprazole
2 Treatment Effect Between Dexlansoprazole and Double-dose Lansoprazole in Obesity Patients With Reflux Esophagitis Unknown status NCT02759393 Phase 4 Dexlansoprazole;Lansoprazole
3 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Wu-Chu-Yu Tang on Gastroesophageal Reflux Disease (GERD) Unknown status NCT01822106 Phase 4
4 Research of Efficient Use of Omeprazole in Combination With Domperidone in Gastroesophageal Reflux Disease of Mild to Moderate Severity Unknown status NCT02140073 Phase 4 omeprazole+domperidone SR;omeprazole
5 The Randomized Controlled Clinical Trial of Kushen Injection Unknown status NCT02346318 Phase 4 Compound Kushen Injection
6 Effect of Magnesium Alginate on Gastroesophageal Reflux in Infants. Unknown status NCT02806453 Phase 4
7 Phase IV Study of the Impact of Dietary Fibers on Symptoms and Esophageal Motility in Patients With Non-erosive GERD Unknown status NCT01882088 Phase 4 Mucofalk
8 Development of Applications of the Bravo® pH Monitoring System and Evaluation of Its Performance Unknown status NCT01503476 Phase 4
9 A Randomized, Double-Blind, Placebo-Controlled Study of Gastroesophageal Reflux Disease Therapy. Unknown status NCT00237068 Phase 4 Lansoprazole; Solutab
10 LGG for Prevention of Infectious Complications During PPI Treatment in Children Unknown status NCT01782118 Phase 4
11 An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis Completed NCT01008696 Phase 4 Rabeprazole;Lansoprazole
12 Intravenous (IV) Pantoprazole in Erosive Esophagitis Completed NCT00133770 Phase 4 pantoprazole
13 Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study Completed NCT00693225 Phase 4 Omeprazole/sodium bicarbonate
14 Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis Completed NCT02371941 Phase 4 oral cromolyn sodium;Placebo
15 Rate of Complete Symptom Relief, Prevention of Symptom Relapse: Grades A and B Esophagitis of Esomeprazole Therapy Completed NCT01874535 Phase 4 Esomeprazole 40 mg
16 A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive Esophagitis Completed NCT00641602 Phase 4 Esomeprazole;Lansoprazole
17 Dietetic Versus Topical Steroids for Pediatric Eosinophilic Esophagitis Completed NCT01846962 Phase 4 Budesonide;Fluticasone;Oral Viscous Budesonide (OVB)
18 Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation Completed NCT03116841 Phase 4 Vonoprazan
19 NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis Completed NCT00206180 Phase 4 esomeprazole magnesium (oral medication)
20 The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD Completed NCT01860482 Phase 4 Newrabell® Tablet 10mg
21 A Study to Evaluate REbamiPide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis Completed NCT02755753 Phase 4 Lansoprazole;Rebamipide;Rebamipide-placebo
22 Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed Completed NCT00644735 Phase 4 Esomeprazole;Lansoprazole
23 Esomeprazole for Treatment of GERD in Pediatric Patients Completed NCT00228527 Phase 4 Esomeprazole (Nexium)
24 An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00242736 Phase 4 Esomeprazole
25 Dexlansoprazole in Asian Participants With Gastroesophageal Reflux Disease Completed NCT02351960 Phase 4 Dexlansoprazole
26 Role of Pepsin Assay in Wheezy Infants Completed NCT02685436 Phase 4 Omeprazole and domperidone
27 To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole Completed NCT01397084 Phase 4 esomeprazole 20 mg
28 Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients Completed NCT00574925 Phase 4 Esomeprazole
29 A Study of Rabeprazole and Pantoprazole on Stomach Acid and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease (GERD) and a History of Nighttime Heartburn Completed NCT00237367 Phase 4 rabeprazole and pantoprazole
30 The Prospective Study on the Effect of Ilaprazole in Non-erosive Reflux Disease Patients; Focused on Histologic Findings and Inflammatory Biomarker Completed NCT02666976 Phase 4 Ilaprazole
31 An Open-Label Trial of Dexlansoprazole 60mg for the Relief of Heartburn During the Fasting Month of Ramadan Completed NCT03079050 Phase 4 Dexlansoprazole 60 MG
32 Do Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux Predict Response to Treatment? Completed NCT00444145 Phase 4 Prevacid
33 Nissen and Gastroplasty in Gastroesophageal Reflux Disease (GERD) Completed NCT00872755 Phase 4
34 Chemotherapy for Patients With Non-Small Cell Lung Cancer Completed NCT00380718 Phase 4 pemetrexed
35 Effect of Citalopram on Reflux Episodes in Healthy Volunteers Completed NCT03746691 Phase 4 Citalopram HCl;Placebos
36 Comparing Clinical Efficacy of One-Week Dual Delayed-Release Dexlansoprazole and Esomeprazole for GERD Grade A and B Completed NCT03128736 Phase 4 Esomeprazole group;Dexlansoprazole group
37 The Effect of Dexrabeprazole on Intragastric and Intraesophageal Acidity Completed NCT02689999 Phase 4 Dexrabeprazole 10 mg Enteric-Coated Tablets
38 Safety and Efficacy of Lansoprazole in Patients With Reflux Disease Completed NCT01135368 Phase 4 Lansoprazole
39 A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI) Completed NCT00734097 Phase 4 Esomeprazole 40 mg
40 Role of Mosapride in Patients With Gastroesophageal Reflux Disease Completed NCT00729339 Phase 4 mosapride for the first month and placebo for the 2nd month;placebo for the first and mosapride for the second month
41 Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US Completed NCT00660660 Phase 4 Esomeprazole;Placebo
42 An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00629564 Phase 4 Esomeprazole;Esomeprazole
43 Open, Randomized, Two Way Crossover Study Comparing the Effect of Esomeprazole Adminstered Orally and iv Completed NCT00626262 Phase 4 Esomeprazole
44 Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00625495 Phase 4 Esomeprazole;Esomeprazole
45 A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40mg Completed NCT00464308 Phase 4 Esomeprazole;Rabeprazole;Esomeprazole
46 Comparison of the Classical Healing Concept With the Complete Remission Concept After Treatment With Pantoprazole in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) (BY1023/M3-342) Completed NCT00325676 Phase 4 Pantoprazole
47 Comparison of the Nighttime Effects of Two Different Drugs on Subjects With GERD Completed NCT00304421 Phase 4 rabeprazole;pantoprazole
48 Esomeprazole in PPI Failures - IMPROVE Completed NCT00272701 Phase 4 Esomeprazole;Other PPI marketed in Sweden
49 Determination of a Questionnaire After Treatment With Pantoprazole at Full Dose and Half Dose in Adult Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/UK-506) Completed NCT00261339 Phase 4 Pantoprazole
50 Determination of the Minimal Clinically Important Difference After Treatment With Pantoprazole in Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-340) Completed NCT00246909 Phase 4 Pantoprazole

Search NIH Clinical Center for Esophagitis

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: esophagitis

Genetic Tests for Esophagitis

Genetic tests related to Esophagitis:

# Genetic test Affiliating Genes
1 Esophagitis 30

Anatomical Context for Esophagitis

MalaCards organs/tissues related to Esophagitis:

42
Testes, Smooth Muscle, Bone, Lymph Node, T Cells, Skin, Breast

Publications for Esophagitis

Articles related to Esophagitis:

(show top 50) (show all 3589)
# Title Authors Year
1
Plasma levels of TNF-α, IL-6, IFN-γ, IL-12, IL-17, IL-22, and IL-23 in achalasia, eosinophilic esophagitis (EoE), and gastroesophageal reflux disease (GERD). ( 30744559 )
2019
2
Eosinophilic esophagitis and achalasia - just a coincidence? ( 30754060 )
2019
3
Deep ulcerative esophagitis: A rare presentation of gastrointestinal actinomycosis. ( 30824406 )
2019
4
Asthma under control is inversely related with erosive esophagitis among healthy adults. ( 30615668 )
2019
5
Lymphocytic Esophagitis: Inflammatory Pattern of Candida Esophagitis in a Patient With Ulcerative Colitis. ( 30651012 )
2019
6
Prevalence of Eosinophilic Esophagitis in Adolescents with Esophageal Atresia. ( 30614952 )
2019
7
Eosinophilic Esophagitis. ( 30466674 )
2019
8
Predictors of Acute Radiation Esophagitis in Non-small Cell Lung Cancer Patients Treated With Accelerated Hyperfractionated Chemoradiotherapy. ( 30591500 )
2019
9
IgG4 is Elevated in Eosinophilic Esophagitis but Not in Gastroesophageal Reflux Disease Patients. ( 30614939 )
2019
10
Sex Differences in the Relation between Waist Circumference within the Normal Range and Development of Reflux Esophagitis. ( 30634537 )
2019
11
Gastroesophageal reflux symptoms and microscopic esophagitis in a cohort of consecutive patients affected by atrophic body gastritis: a pilot study. ( 30638085 )
2019
12
Gender-specific Effect of Micronutrient on Non-erosive Reflux Disease and Erosive Esophagitis. ( 30646479 )
2019
13
Symptom-based patient-reported outcomes in adults with eosinophilic esophagitis: value for treatment monitoring and randomized controlled trial design. ( 30649010 )
2019
14
A rare case report of fungal esophagitis combined with giant gastric ulcer in an immunocompetent patient. ( 30653156 )
2019
15
Lymphocytic esophagitis updated. ( 30653662 )
2019
16
Unusual manifestation of disseminated herpes simplex virus type 2 infection associated with pharyngotonsilitis, esophagitis, and hemophagocytic lymphohisitocytosis without genital involvement. ( 30654754 )
2019
17
A 12-Week Maintenance Therapy with a New Prepared Viscous Budesonide in Pediatric Eosinophilic Esophagitis. ( 30659470 )
2019
18
Association Between Helicobacter pylori Exposure and Decreased Odds of Eosinophilic Esophagitis-a Systematic Review and Meta-analysis. ( 30659992 )
2019
19
Effects of Abdominal Visceral Fat Change on Regression of Erosive Esophagitis. ( 30665276 )
2019
20
Black Esophagus (Acute Necrotizing Esophagitis) and Wischnewsky Lesions in a Death From Diabetic Ketoacidosis: A Possible Underlying Mechanism. ( 30676335 )
2019
21
Dabigatran-Induced Esophagitis Associated With Vomiting. ( 30676363 )
2019
22
No Maintenance, No Gain in Long-term Treatment of Eosinophilic Esophagitis. ( 30678839 )
2019
23
Refractory Severe Esophagitis During Durvalumab Therapy in a Patient With Locally Advanced NSCLC. ( 30683299 )
2019
24
New IgE Immediate Hypersensitivity Reactions Upon Reintroduction of Food Restricted for Treatment of Eosinophilic Esophagitis. ( 30684739 )
2019
25
New Developments in the Diagnosis and Treatment of Eosinophilic Esophagitis. ( 30707411 )
2019
26
Transnasal Endoscopy in Unsedated Children With Eosinophilic Esophagitis Using Virtual Reality Video Goggles. ( 30708107 )
2019
27
A conceptual approach to understanding treatment response in eosinophilic esophagitis. ( 30710696 )
2019
28
A Comparative Analysis of Eating Behavior of School-Aged Children with Eosinophilic Esophagitis and Their Caregivers' Quality of Life: Perspectives of Caregivers. ( 30712065 )
2019
29
Management of eosinophilic esophagitis is often discordant with guidelines and not patient-centered: results of a survey of gastroenterologists. ( 30715230 )
2019
30
Screening children for eosinophilic esophagitis: allergic and other risk factors. ( 30722709 )
2019
31
Variations in the Clinical Course of Patients with Herpes Simplex Virus Esophagitis Based on Immunocompetence and Presence of Underlying Esophageal Disease. ( 30725296 )
2019
32
Assessing the Risk Factors for Refractory Eosinophilic Esophagitis in Children and Adults. ( 30755767 )
2019
33
What is the impact of metabolic syndrome and its components on reflux esophagitis? A cross-sectional study. ( 30782138 )
2019
34
Eosinophilic Esophagitis-A Primer for Otolaryngologists. ( 30789641 )
2019
35
Molecular basis and cellular mechanisms of eosinophilic esophagitis for the clinical practice. ( 30791784 )
2019
36
Oral glutamine supplements reduce concurrent chemoradiotherapy-induced esophagitis in patients with advanced non-small cell lung cancer. ( 30813149 )
2019
37
Changes in Clock Genes Expression in Esophagus in Rat Reflux Esophagitis. ( 30815822 )
2019
38
Eosinophilic esophagitis: Pathophysiology, diagnosis, and management. ( 30827775 )
2019
39
Subcutaneous immunotherapy in patients with eosinophilic esophagitis. ( 30831258 )
2019
40
Exfoliative Esophagitis Induced By Sunitinib. ( 30832801 )
2019
41
Food impaction: etiology over 35 years and association with eosinophilic esophagitis. ( 30847465 )
2019
42
Eosinophilic esophagitis after total gastrectomy treated with proton pump inhibitors: a case report. ( 30848447 )
2019
43
Penetration of the Esophageal Epithelium by Dust Mite Antigen in Patients With Eosinophilic Esophagitis. ( 30849319 )
2019
44
Impact of Chronic Statins Use on the Development of Esophagitis in Patients with Gastroesophageal Reflux Disease. ( 30854351 )
2019
45
Application of Computed Tomography to Diagnose Fungal Esophagitis: One Case Report. ( 30855161 )
2019
46
Mediastinal abscess, an unusual way of presentation of eosinophilic esophagitis. ( 30858868 )
2019
47
Efficacy of Budesonide vs Fluticasone for Initial Treatment of Eosinophilic Esophagitis in a Randomized Controlled Trial. ( 30872104 )
2019
48
Sustained Remission of Eosinophilic Esophagitis Following Discontinuation of Dietary Elimination in Children. ( 30880275 )
2019
49
Diagnosis of Eosinophilic Esophagitis in Children - A Serbian Single Center Experience from 2010 to 2017. ( 30884488 )
2019
50
Combination Therapy with Elimination Diet and Corticosteroids is Effective for Adults with Eosinophilic Esophagitis. ( 30885887 )
2019

Variations for Esophagitis

Expression for Esophagitis

Search GEO for disease gene expression data for Esophagitis.

Pathways for Esophagitis

Pathways related to Esophagitis according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.02 CCL11 CXCL8 DSG1 IL13 IL1B IL5
2
Show member pathways
13.85 CCL11 CCL26 CCR3 CXCL8 IL13 IL1B
3
Show member pathways
13.56 CCL11 CCL26 CCR3 CXCL8 IL13 IL1B
4
Show member pathways
13.55 CCL11 CCL26 CXCL8 IL13 IL1B IL5
5
Show member pathways
13.4 CCL11 CCL26 CCR3 CXCL8 IL13 IL1B
6
Show member pathways
13.37 CCL11 CXCL8 IL13 IL1B IL5 IL6
7
Show member pathways
13.29 CCL11 CCL26 CCR3 CXCL8 IL13 IL1B
8
Show member pathways
12.98 CCR3 CXCL8 IL1B IL6 PTGS2 TGFB1
9
Show member pathways
12.89 CCL11 CXCL8 IL13 IL1B IL5 IL6
10 12.85 CXCL8 IL13 IL5 IL6 PTGS2 TGFB1
11
Show member pathways
12.61 IL13 IL1B IL5 IL6 TGFB1
12
Show member pathways
12.58 CXCL8 IL13 IL1B IL6 TP53
13
Show member pathways
12.44 IL13 IL1B IL5 TP53
14
Show member pathways
12.42 IL1B IL5 IL6 TGFB1
15
Show member pathways
12.39 IL13 IL5 IL6 TSLP
16
Show member pathways
12.36 IL1B IL6 PTGS2 SOD2 TP53
17
Show member pathways
12.35 CXCL8 IL1B IL6 PTGS2 TP53
18
Show member pathways
12.34 CCL11 CCL26 CCR3 CXCL8
19
Show member pathways
12.33 CCL11 CXCL8 IL13 IL1B IL5 IL6
20
Show member pathways
12.29 CXCL8 IL13 IL1B IL5 IL6 TGFB1
21
Show member pathways
12.24 CXCL8 IL1B IL6 PTGS2
22
Show member pathways
12.22 CCL11 CCL26 CCR3 CXCL8 IL1B
23
Show member pathways
12.2 CCL11 CXCL8 IL1B IL6
24 12.2 IL6 PTGS2 TGFB1 TP53
25 12.19 CXCL8 IL13 IL1B IL6
26 12.18 CXCL8 IL6 TGFB1 TP53
27
Show member pathways
12.06 IL13 IL1B IL5 TP53
28
Show member pathways
12.05 CCL11 CCL26 CXCL8 IL13 IL1B IL5
29
Show member pathways
12.03 CCL11 CCL26 CCR3 CXCL8
30 12.03 CXCL8 IL1B IL6 PTGS2 TGFB1 TP53
31 11.99 CXCL8 IL1B IL6 TGFB1 TP53
32 11.97 CCR3 IL5 IL6
33 11.97 SOD2 TGFB1 TP53
34 11.96 CXCL8 IL1B IL6 TGFB1
35 11.95 IL1B IL6 PTGS2
36 11.93 CXCL8 IL1B IL6 TGFB1
37 11.91 CXCL8 IL1B IL6 TGFB1
38 11.89 IL1B IL5 IL6
39 11.88 CXCL8 IL1B PTGS2
40
Show member pathways
11.86 CXCL8 IL6 TGFB1
41 11.86 CXCL8 IL13 IL5 IL6 TP53
42 11.83 CXCL8 IL1B IL6
43 11.83 IL13 IL1B IL5 TSLP
44
Show member pathways
11.77 CXCL8 IL5 PTGS2
45 11.76 CXCL8 IL1B IL6
46 11.75 IL1B IL6 TGFB1
47
Show member pathways
11.72 CXCL8 IL1B IL6 PTGS2
48 11.67 CCL11 CCL26 IL5
49 11.62 CXCL8 IL6 PTGS2 TGFB1 TP53
50 11.61 CXCL8 IL1B IL6

GO Terms for Esophagitis

Cellular components related to Esophagitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 CCL11 CCL26 CXCL8 IL13 IL1B IL5
2 extracellular space GO:0005615 9.32 CCL11 CCL26 CXCL8 IL13 IL1B IL5

Biological processes related to Esophagitis according to GeneCards Suite gene sharing:

(show all 39)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.91 CCL11 CCL26 CCR3 CXCL8 HRH2 IL13
2 positive regulation of cell migration GO:0030335 9.89 CCL11 CCL26 IL1B SOD2 TGFB1
3 chemotaxis GO:0006935 9.88 CCL11 CCL26 CCR3 CXCL8
4 positive regulation of angiogenesis GO:0045766 9.87 CCL11 CCR3 CXCL8 IL1B
5 negative regulation of cell proliferation GO:0008285 9.87 CXCL8 IL1B IL6 PTGS2 SOD2 TGFB1
6 positive regulation of DNA-binding transcription factor activity GO:0051091 9.85 IL1B IL5 IL6
7 cellular response to tumor necrosis factor GO:0071356 9.85 CCL11 CCL26 CXCL8 POSTN
8 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.83 IL6 PTGS2 TGFB1
9 cellular response to interleukin-1 GO:0071347 9.83 CCL11 CCL26 CXCL8
10 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.82 CCL11 CCL26 TGFB1
11 positive regulation of endothelial cell proliferation GO:0001938 9.81 CCL11 CCL26 CCR3
12 regulation of signaling receptor activity GO:0010469 9.81 CCL11 CCL26 CXCL8 IL13 IL1B IL5
13 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.8 IL13 IL6 TSLP
14 positive regulation of interleukin-6 production GO:0032755 9.79 IL1B IL6 TSLP
15 positive regulation of smooth muscle cell proliferation GO:0048661 9.79 IL13 IL6 PTGS2
16 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.78 IL5 IL6 TGFB1 TP53
17 monocyte chemotaxis GO:0002548 9.75 CCL11 CCL26 IL6
18 response to radiation GO:0009314 9.73 CCL11 PTGS2 TGFB1
19 neutrophil chemotaxis GO:0030593 9.73 CCL11 CCL26 CXCL8 IL1B
20 cellular response to mechanical stimulus GO:0071260 9.71 IL13 IL1B PTGS2 TGFB1
21 positive regulation of vascular endothelial growth factor production GO:0010575 9.7 IL1B PTGS2 TGFB1
22 response to estradiol GO:0032355 9.69 POSTN PTGS2 TGFB1
23 positive regulation of glial cell proliferation GO:0060252 9.68 IL1B IL6
24 positive regulation of chemotaxis GO:0050921 9.67 CCL26 TGFB1
25 wound healing GO:0042060 9.67 POSTN TGFB1
26 chemokine-mediated signaling pathway GO:0070098 9.67 CCL11 CCL26 CCR3 CXCL8
27 positive regulation of immunoglobulin secretion GO:0051024 9.66 IL5 IL6
28 memory GO:0007613 9.65 HRH2 PTGS2
29 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.64 TGFB1 TP53
30 response to glucocorticoid GO:0051384 9.62 IL6 PTGS2
31 positive regulation of neuroinflammatory response GO:0150078 9.61 IL1B IL6
32 cytokine-mediated signaling pathway GO:0019221 9.61 CCL11 CXCL8 IL13 IL1B IL5 IL6
33 positive regulation of fever generation GO:0031622 9.59 IL1B PTGS2
34 response to vitamin D GO:0033280 9.46 PTGS2 TGFB1
35 ovulation GO:0030728 9.36 PTGS2
36 inflammatory response GO:0006954 9.32 CCL11 CCL26 CCR3 CXCL8 IL13 IL1B
37 positive regulation of transcription, DNA-templated GO:0045893 10.07 IL1B IL5 IL6 TGFB1 TP53
38 positive regulation of cell proliferation GO:0008284 10.01 IL1B IL5 IL6 PTGS2 TGFB1 TSLP
39 positive regulation of gene expression GO:0010628 10 IL13 IL1B IL6 TGFB1 TP53

Molecular functions related to Esophagitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine activity GO:0008009 9.33 CCL11 CCL26 CXCL8
2 cytokine activity GO:0005125 9.28 CCL11 CCL26 CXCL8 IL13 IL1B IL5
3 CCR3 chemokine receptor binding GO:0031728 8.96 CCL11 CCL26

Sources for Esophagitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....